Instrument Sale to Novo Nordisk for Group Evaluation
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The evaluation will assess the performance of the APAS® technology in reading microbiology culture plates used in environmental monitoring. This sale aligns with the company's strategy to partner with major pharmaceutical manufacturers to improve their practices globally. The company expects to announce further evaluations and sales to additional large multinational pharmaceutical customers in the upcoming fiscal year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clever Culture Systems Limited on 6ix
Earlier from Clever Culture Systems
- Additional Four Instruments Ordered by AstraZeneca
- LBT Announce Bristol Myers Squibb Purchase APAS Independence
- Astrazeneca sale & service contract up to a$4.1M
- Response to ASX Price Query
- Lift of Pause in Trading
Later from Clever Culture Systems
- APAS Contact Plate Application Product Launch
- Appendix 4E
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Proposed issue of securities - CC5
Follow Clever Culture Systems into a list and get an email when it puts out news.
Follow Clever Culture Systems